Cited by 77Treatment of Major DepressionAnxiety, Depression, Psychometrics, Treatment, Cognitive ProcessesElectroconvulsive Therapy Studies

Difference in remission in a Chinese population with anxious versus nonanxious treatment-resistant depression: a report of OPERATION study

Wu, Zhiguo, Chen, Jun, Yuan, Chengmei, Hong, Wu, Peng, Daihui, Zhang, Chen, Cao, Lan, Fang, Yiru·2013·Journal of Affective Disorders

Abstract

Background A secondary analysis was conducted to compare treatment outcomes for anxious depression and nonanxious depression in previous published OPERATION trials of a variety of antidepressants and augmentation strategies for patients with treatment-resistant depression (TRD).Methods A total of 375 patients that met DSM-IV criteria for major depressive disorder (MDD) and the stage 2 TRD criteria (described by Thase & Rush) were enrolled. Anxious depression was defined as MDD with a HRSD-17 anxiety/somatization factor score ≥7. Data were derived from an earlier study, designed to compare efficacy and tolerability of fixed dosage of extended-release venlafaxine, mitazapine, paroxetine, and risperidone, sodium valproate, buspirone, trazodone or thyroid hormone augmenting to paroxetine in those patients. Treatment outcomes were compared between patients with anxious and nonanxious TRD.Results Nearly 70% of participants had anxious depression. Remission rates were significantly lower and ratings of adverse event frequency were significantly greater in patients with anxious TRD than in those with nonanxious TRD. Presence of anxious depression predicted worse outcomes.Limitations Lack of a placebo control arm prevents us from ruling out placebo effects. The two groups were non-randomly allocated to medications. Only patients with stage 2 TRD were enrolled, which may limit generalizablity to patients without a history of resistance. Comorbid anxiety disorders that might confound the specific treatment effects were not addressed.Conclusions The findings support and extend the hypothesis that anxious depression is associated with poorer outcomes. It suggests a dimensional assessment of co-occurring anxious features of MDD patients may be clinically feasible for countries like China where difficulties in making comorbidity diagnosis exist.

Integrity signals

Registry

Crossref · 10.1016/j.jad.2013.03.012

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

2 of the 28 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Wu, Z., Chen, J., Yuan, C., Hong, W., Peng, D., Zhang, C., Cao, L., & Fang, Y.
Affiliations
Shanghai Jiao Tong University (CN)
Corresponding author
Fang, Yiru
Venue
Journal of Affective Disorders
Publisher
Elsevier BV
Published
2013-09
Volume
150
Issue
3
Pages
834-839
ISSN
0165-0327 (ISSN-L)
OpenAlex
W1970407368
Cited by
77
References
28
Citations by year
2026: 1 · 2025: 8 · 2024: 10 · 2023: 2 · 2022: 8 · 2021: 4 · 2020: 4 · 2019: 10 · 2018: 13 · 2017: 4 · 2016: 3 · 2015: 5 · 2014: 3 · 2013: 2
FWCI
3.18
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Affective Disorders (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
Keywords
treatment-resistant depression, anxious depression, remission, major depressive disorder, antidepressant augmentation, venlafaxine, paroxetine, risperidone, valproic acid, buspirone, trazodone, adverse events, anxiety comorbidity, Chinese patients
MeSH terms
Venlafaxine Hydrochloride, Adolescent, Adult, Aged, Antidepressive Agents, Anxiety Disorders, Buspirone, China, Cyclohexanols, Major Depressive Disorder, Double-Blind Method, Female, Humans, Male, Middle Aged, Remission Induction, Comorbidity, Treatment Outcome, Paroxetine, Risperidone, Young Adult, Depressive Disorder, Treatment-Resistant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review